Alnylam and Inceptive have reached a strategic AI collaboration to accelerate the development of RNAi therapy On June 3, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) and lnceptive Nucleics, a company dedicated to building life science foundation models, announced today that they have signed a strategic partnership agreement aimed at accelerating the development of innovative therapeutic drugs
3.5 NK cells Harnessing innate immunity to expand antitumor responses is an attractive strategy
It enhances glucose balance by targeting the GLP-1, GIP, and glucagon receptors
ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of rDNA origin guidance for industry
GLP-1 Supplements and Herbal Drops Products sold as GLP-1 gummies or GLP-1 drops are generally herbal supplements marketed as natural GLP-1 boosters
GLUTAG 600MG INJECTION 1 is primarily designed to support liver health and is not specifically intended for skin-related conditions